FDA Approved: RETEVMO — Original Application (Eli Lilly and Company)

View source ↗

Summary

FDA approved Retevmo (selpercatinib) from Eli Lilly in its original NDA. The approval covers RET fusion-positive non-small cell lung cancer and RET fusion-posit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma
• Non-small Cell Lung Cancer
• Papillary Thyroid Carcinoma

Drugs mentioned

• RETEVMO (selpercatinib)

Snippet

ORIG AP for RETEVMO (SELPERCATINIB)